Product References
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
PloS one
Muñoz R,Hileeto D,Cruz-Muñoz W,Wood GA,Xu P,Man S,Viloria-Petit A,Kerbel RS
Published figure using c-Met monoclonal antibody (Product # 18-7366) in Immunohistochemistry
Fri Mar 06 00:00:00 EST 2020
Development of a Novel c-MET-Based CTC Detection Platform.
Molecular cancer research : MCR
Zhang T,Boominathan R,Foulk B,Rao C,Kemeny G,Strickler JH,Abbruzzese JL,Harrison MR,Hsu DS,Healy P,Li J,Pi C,Prendergast KM,Hobbs C,Gemberling S,George DJ,Hurwitz HI,Connelly M,Garcia-Blanco MA,Armstrong AJ
18-7366 was used in immunocytochemistry to elucidate a unique c-MET-based CTC detection platform
Wed Jun 01 00:00:00 EDT 2016
Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.
eLife
Morena D,Maestro N,Bersani F,Forni PE,Lingua MF,Foglizzo V,Šćepanović P,Miretti S,Morotti A,Shern JF,Khan J,Ala U,Provero P,Sala V,Crepaldi T,Gasparini P,Casanova M,Ferrari A,Sozzi G,Chiarle R,Ponzetto C,Taulli R
Published figure using c-Met monoclonal antibody (Product # 18-7366) in Immunohistochemistry
Thu Mar 17 00:00:00 EDT 2016
Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes.
eLife
Morena D,Maestro N,Bersani F,Forni PE,Lingua MF,Foglizzo V,Šćepanović P,Miretti S,Morotti A,Shern JF,Khan J,Ala U,Provero P,Sala V,Crepaldi T,Gasparini P,Casanova M,Ferrari A,Sozzi G,Chiarle R,Ponzetto C,Taulli R
Published figure using c-Met monoclonal antibody (Product # 18-7366) in Immunohistochemistry
Thu Mar 17 00:00:00 EDT 2016
MET is required for the recruitment of anti-tumoural neutrophils.
Nature
Finisguerra V,Di Conza G,Di Matteo M,Serneels J,Costa S,Thompson AA,Wauters E,Walmsley S,Prenen H,Granot Z,Casazza A,Mazzone M
18-7366 was used in ELISA and western blot to report that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor.
Thu Jun 18 00:00:00 EDT 2015
MET is required for the recruitment of anti-tumoural neutrophils.
Nature
Finisguerra V,Di Conza G,Di Matteo M,Serneels J,Costa S,Thompson AA,Wauters E,Walmsley S,Prenen H,Granot Z,Casazza A,Mazzone M
18-7366 was used in ELISA and western blot to report that MET is required for neutrophil chemoattraction and cytotoxicity in response to its ligand hepatocyte growth factor.
Thu Jun 18 00:00:00 EDT 2015
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Oncotarget
Mahadevan D,Theiss N,Morales C,Stejskal AE,Cooke LS,Zhu M,Kurtzman D,Swart R,Ong E,Qi W
187366 was used in western blot to discuss the limitations of c-Kit/PDGFR-targeted therapies for treatment of gastrointestinal stromal tumors
Tue Feb 10 00:00:00 EST 2015
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Oncology reports
Marchion DC,Bicaku E,Xiong Y,Bou Zgheib N,Al Sawah E,Stickles XB,Judson PL,Lopez AS,Cubitt CL,Gonzalez-Bosquet J,Wenham RM,Apte SM,Berglund A,Lancaster JM
18-7366 was used in Immunocytochemistry experiments to evaluate the role of the hepatocyte growth factor signalling pathway in ovarian cancer cell line chemoresistance and patient survival.
Wed May 01 00:00:00 EDT 2013
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Nature
Straussman R,Morikawa T,Shee K,Barzily-Rokni M,Qian ZR,Du J,Davis A,Mongare MM,Gould J,Frederick DT,Cooper ZA,Chapman PB,Solit DB,Ribas A,Lo RS,Flaherty KT,Ogino S,Wargo JA,Golub TR
18-7366 was used in immunohistochemistry - paraffin section to develop and use a co-culture system to systematically assay the influence of 23 stromal cell types on the innate resistance of 45 cancer cell lines to 35 anticancer drugs.
Thu Jul 26 00:00:00 EDT 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Nature
Straussman R,Morikawa T,Shee K,Barzily-Rokni M,Qian ZR,Du J,Davis A,Mongare MM,Gould J,Frederick DT,Cooper ZA,Chapman PB,Solit DB,Ribas A,Lo RS,Flaherty KT,Ogino S,Wargo JA,Golub TR
18-7366 was used in immunohistochemistry - paraffin section to develop and use a co-culture system to systematically assay the influence of 23 stromal cell types on the innate resistance of 45 cancer cell lines to 35 anticancer drugs.
Thu Jul 26 00:00:00 EDT 2012
MET and phosphorylated MET as potential biomarkers in lung cancer.
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
Tretiakova M,Salama AK,Karrison T,Ferguson MK,Husain AN,Vokes EE,Salgia R
18-7366 was used in immunohistochemistry to assess expression and prognostic role of the receptor tyrosine kinase MET, phosphorylated MET, and the ligand hepatocyte growth factor in patients with lung cancer.
Thu Feb 16 00:00:00 EST 2012
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Cancer research
Seiwert TY,Jagadeeswaran R,Faoro L,Janamanchi V,Nallasura V,El Dinali M,Yala S,Kanteti R,Cohen EE,Lingen MW,Martin L,Krishnaswamy S,Klein-Szanto A,Christensen JG,Vokes EE,Salgia R
18-7366 was used in western blot to study MET receptor tyrosine kinase as a potential novel therapeutic target for head and neck squamous cell carcinoma
Wed Apr 01 00:00:00 EDT 2009
Prognostic significance of c-Met expression in glioblastomas.
Cancer
Kong DS,Song SY,Kim DH,Joo KM,Yoo JS,Koh JS,Dong SM,Suh YL,Lee JI,Park K,Kim JH,Nam DH
187366 was used in immunohistochemistry - paraffin section to test if c-Met expression is associated with overall survival and tumor invasiveness in patients with glioblastomas
Thu Jan 01 00:00:00 EST 2009